53 image-coding-"Foundation-for-Research-and-Technology-Hellas" Postdoctoral positions in Denmark
Sort by
Refine Your Search
-
Listed
-
Employer
-
Field
-
frameworks, applying existing frameworks, and implementing novel methodology in shared code repositories. You will also assist in instructing and guiding the research of MSc and PhD students. Qualifications As
-
, HPLC, analytical chemistry and image analysis. Self-driven, highly motivated, organized, and responsible individual Team player We offer DTU is a leading technical university globally recognized
-
associated with the ‘Biomedical Mass Spectrometry and Systems Biology research unit’ at BMB and the ‘Danish National Mass Spectrometry Platform for Proteomics and Biomolecular Imaging’ (PLATO), which provides
-
facilities in imaging, immunology, tissue engineering, and bioinformatics. Qualifications We seek applicants with the following qualifications: Essential: PhD in molecular biology, immunology, biochemistry
-
Crystallography Physical Metallurgy Experience with synchrotrons or laboratory 3D diffraction imaging is considered as a significant advantage. Excellent English communication skills are also essential. As a formal
-
the pdf-files into a single file, as each field handles only one file. We do not accept zip-files, jpg or other image files. All pdf-files must be unlocked and allow binding and may not be password
-
the application online in Adobe PDF or Word format. Please click on the “Apply now” icon at the bottom of this page. The application must be written in English and include the following enclosures: Application
-
to define how RecQ helicases maintain genome stability to limit premature aging and cancer development. These projects will benefit from access to cutting-edge mass spectrometry, imaging, screening and
-
portal . Click on the “Apply now” icon at the bottom of the page to apply. The documents must be in Adobe PDF or Word. The application must be written in English and include the following documents
-
) quantification tools, holding back early immunogenicity risk assessment in the context of protein drug development. A clearer understanding of the rules governing T cell activation would form a paradigm shift in